{"product_id":"jnj-bcg-matrix","title":"(JNJ) Johnson \u0026 Johnson BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Johnson \u0026amp; Johnson BCG Matrix helps you quickly see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDarzalex: 2024 sales about $11.7B, multiple myeloma leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDarzalex delivered about $11.7 billion in 2024 sales, making it Johnson \u0026amp; Johnson’s biggest growth engine in Innovative Medicine. Its share stays strong as use expands into earlier-line multiple myeloma and more combo regimens, with demand still rising across key markets. That scale, plus durable dominance in a large oncology category, makes Darzalex a clear Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTremfya: 2024 sales about $3.8B, fast-growth immunology brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTremfya posted about $3.8 billion in 2024 sales, and Johnson \u0026amp; Johnson said the brand kept growing across psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. With approvals now spanning major inflammatory diseases, it is still in an early expansion phase and keeps winning share in a large specialty market. That mix of strong growth and widening leadership fits the Star box.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpravato: 2024 sales above $1B, rapid CNS growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpravato posted more than $1B in 2024 sales, making it one of Johnson \u0026amp; Johnson’s fastest-growing CNS assets. Demand is still rising on treatment-resistant depression use, and access is widening in specialty clinics. It still needs heavy commercial support, but that growth profile fits a Star in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eImpella platform: about $1B annual sales, high-growth heart recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImpella, the Abiomed platform, sits near $1B annual sales and remains a key MedTech growth engine. Temporary mechanical circulatory support is still in fast growth, and Impella’s strong share in high-acuity heart recovery supports a Star label in the BCG Matrix. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAbout $1B annual sales\u003c\/li\u003e\n\u003cli\u003eFast-growing tMCS market\u003c\/li\u003e\n\u003cli\u003eStrong market position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosense Webster electrophysiology: leader in 2025 ablation growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiosense Webster stays a Star because electrophysiology is still one of MedTech’s fastest-growing areas, and J\u0026amp;J has a deep installed base in mapping and ablation. In 2025, pulse field ablation kept adoption moving faster, with centers upgrading to newer systems rather than standing still.\u003c\/p\u003e\n\u003cp\u003eThe share-and-growth mix is strong: a leading position in a market expanding on AFib volume and newer ablation tech supports Star status in the BCG Matrix. One line says it simply: share is high, and the runway is still long.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast-growing electrophysiology demand\u003c\/li\u003e\n\u003cli\u003eStrong mapping and ablation base\u003c\/li\u003e\n\u003cli\u003ePulse field ablation adds momentum\u003c\/li\u003e\n\u003cli\u003eHigh share in a growing market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s Star Brands Are Driving Big Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s Stars are led by Darzalex at $11.7B and Tremfya at $3.8B in 2024, with Spravato topping $1B and Impella near $1B. Biosense Webster also fits, as electrophysiology demand stayed strong and pulse field ablation sped adoption in 2025. These brands pair high share with fast market growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex\u003c\/td\u003e\n\u003ctd\u003e$11.7B\u003c\/td\u003e\n\u003ctd\u003eMyeloma growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTremfya\u003c\/td\u003e\n\u003ctd\u003e$3.8B\u003c\/td\u003e\n\u003ctd\u003eNew launches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpravato\u003c\/td\u003e\n\u003ctd\u003e$1B+\u003c\/td\u003e\n\u003ctd\u003eRising demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eJohnson \u0026amp; Johnson BCG Matrix: maps key businesses into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eJohnson \u0026amp; Johnson BCG Matrix: quick quadrant view to spot pain points and prioritize growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eJohnson \u0026amp; Johnson Reference Sources provide a traceable credibility trail, helping decision-makers verify key claims fast and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelara: 2024 sales about $10.4B, mature immunology blockbuster\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStelara remains a cash cow for Johnson \u0026amp; Johnson, with 2024 sales of about $10.4 billion and a long run of high-margin, scale-driven profits. In 2025, biosimilar launches in the U.S. and Europe are starting to pressure revenue, but the brand still throws off strong cash from its installed patient base. With growth slowing and the franchise now mature, Stelara fits the BCG Cash Cow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvega Sustenna family: about $4B annual franchise, mature psychiatry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInvega Sustenna and the Invega family remain a mature cash cow for Johnson \u0026amp; Johnson, with franchise sales running at about $4 billion a year. The long-acting injectable holds a strong position in schizophrenia maintenance, and the business has shown steady demand with only modest growth. With low promotion needs and established prescriber loyalty, it keeps generating reliable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimponi and Simponi Aria: mature rheumatology biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimponi and Simponi Aria are mature rheumatology biologics with steady recurring demand, but growth is limited as the franchise has aged. In Johnson \u0026amp; Johnson's 2025 reporting, the immunology portfolio still generated meaningful sales, yet these brands sit in a low-growth, high-share position. That is classic Cash Cow territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eACUVUE contact lenses: global scale, steady replacement demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eACUVUE is a repeat-purchase MedTech brand, so demand refreshes with each replacement cycle. The category is mature and growth is slow, but Johnson \u0026amp; Johnson still gets broad global distribution and strong brand recall, which supports steady cash flow. That makes ACUVUE a classic Cash Cow in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat demand\u003c\/li\u003e\n\u003cli\u003eMature market\u003c\/li\u003e\n\u003cli\u003eWide distribution\u003c\/li\u003e\n\u003cli\u003eStable cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDePuy Synthes hips and knees: large installed base, low-growth orthopaedics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDePuy Synthes hips and knees sit in a mature orthopaedics market where implants last years and hospital contracts are hard to dislodge. With Johnson \u0026amp; Johnson still a top global player, the unit acts like a Cash Cow: steady replacement demand, low growth, and cash generation that usually exceeds reinvestment needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge installed base\u003c\/li\u003e\n\u003cli\u003eSticky hospital relationships\u003c\/li\u003e\n\u003cli\u003eLong product cycles\u003c\/li\u003e\n\u003cli\u003eHigh cash conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s Cash Cows Keep the Growth Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s Cash Cows are mature, low-growth brands with strong installed demand and steady cash conversion. Stelara led at about $10.4 billion in 2024 sales, while Invega Sustenna and the Invega family ran near $4 billion, and Simponi, ACUVUE, and DePuy Synthes hips and knees added stable, recurring cash in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025\/2024 sales\u003c\/th\u003e\n\u003cth\u003eWhy Cash Cow\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelara\u003c\/td\u003e\n\u003ctd\u003eAbout $10.4B\u003c\/td\u003e\n\u003ctd\u003eHigh share, mature market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvega family\u003c\/td\u003e\n\u003ctd\u003eAbout $4B\u003c\/td\u003e\n\u003ctd\u003eSticky demand, low promo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eJohnson \u0026amp; Johnson Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Johnson \u0026amp; Johnson BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the complete, professionally formatted file. Once purchased, it’s ready for immediate use in analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemicade: biosimilar erosion, low growth by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRemicade fits the Dog box: it was once a \u0026gt;$7 billion blockbuster, but biosimilar infliximab copies and newer immunology drugs have stripped away most growth. By 2025, the market is mature, low growth, and Remicade’s share is far below its peak, so it no longer drives meaningful upside for Johnson \u0026amp; Johnson.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZytiga: generic prostate cancer franchise, shrinking contribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZytiga is now a mature prostate cancer asset with heavy generic competition, so its sales contribution to Johnson \u0026amp; Johnson keeps shrinking. Newer prostate cancer drugs have taken share, and Zytiga’s growth is now low to negative, which fits the Dog box in the BCG Matrix. In 2025, it is a legacy oncology brand, not a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVelcade: older myeloma therapy, limited market momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVelcade, launched in 2003, is a 20+ year-old multiple myeloma therapy that now plays a much smaller role in Johnson \u0026amp; Johnson’s oncology mix. The market has shifted to newer, higher-value drugs, while Velcade faces intense generic pressure and little growth. In BCG terms, it fits a Dog: low share, low momentum, and limited capital priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy spine hardware: commoditized MedTech, weak growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy spine hardware in Johnson \u0026amp; Johnson is a Dog: older implant lines face price cuts, low switching costs, and a mature spine market that grows only in low single digits. In MedTech, capital is flowing to faster areas like robotics and digital surgery, so this niche gets less growth and weaker margin support.\u003c\/p\u003e\n\u003cp\u003eHigh competition from Medtronic, Globus Medical, and NuVasive keeps differentiation thin, while reimbursement pressure limits pricing power. Result: slow growth, modest share gains, and low strategic priority inside Johnson \u0026amp; Johnson.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth\u003c\/li\u003e\n\u003cli\u003eHeavy price pressure\u003c\/li\u003e\n\u003cli\u003eWeak differentiation\u003c\/li\u003e\n\u003cli\u003eDog in BCG terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder surgical and wound products: flat demand, low strategic priority\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson's older surgical and wound lines are maintained, not scaled. In 2024, Johnson \u0026amp; Johnson reported $30.4 billion in MedTech sales, but these legacy products added little growth, so they fit BCG Dog behavior: low share, low momentum, and limited capital priority.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFlat demand, weak growth\u003c\/li\u003e\n\u003cli\u003eKept for service and shelf breadth\u003c\/li\u003e\n\u003cli\u003eLow capex, low strategic focus\u003c\/li\u003e\n\u003cli\u003eDog-like asset in BCG terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s Dogs: Legacy Assets Losing Ground in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s Dogs are legacy assets with weak growth and shrinking share: Remicade, Zytiga, and Velcade face biosimilars or generics, while older spine, surgical, and wound lines sit in mature markets with price pressure. They add little upside in 2025, so capital is better shifted to faster-growth platforms.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemicade\u003c\/td\u003e\n\u003ctd\u003eBio-similar erosion\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZytiga\u003c\/td\u003e\n\u003ctd\u003eGeneric decline\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVelcade\u003c\/td\u003e\n\u003ctd\u003eLow share, low growth\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy MedTech lines\u003c\/td\u003e\n\u003ctd\u003eMature, price-pressured\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti: 2024 sales around $1B, fast-growing but still small share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCarvykti posted 2024 sales of $963 million, up 92% year over year, but that is still small versus the multiple myeloma opportunity. J\u0026amp;J still faces manufacturing scale and market access limits, so growth can be choppy. That makes Carvykti a Question Mark with Star potential if supply and reimbursement keep improving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTecvayli: 2024 sales under $0.5B, growing bispecific launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTecvayli posted about $0.5B in 2024 sales, still small for Johnson \u0026amp; Johnson but growing fast as a T-cell engager in multiple myeloma. The bispecific class is expanding from a low base, so Tecvayli fits a Question Mark: high growth, low share. J\u0026amp;J can either spend hard to build share or leave it as a niche asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTalvey: 2024 sales under $0.2B, early myeloma expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTalvey is still a Question Mark in Johnson \u0026amp; Johnson’s BCG mix: 2024 sales were about $0.18 billion, so it is far below the company’s top cancer products. It serves the growing multiple myeloma market, but its share is still small because it is early in launch and not yet a proven leader. The upside is real, but scale and adoption must rise fast to move it out of the low-share, high-growth box.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNipocalimab: Phase 3 FcRn asset, zero 2025 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNipocalimab sits in J\u0026amp;J’s Question Mark bucket: a Phase 3 FcRn antibody aimed at large autoimmune and maternal-fetal disease markets, but with 2025 sales at $0 because it is still in development. FcRn is a neonatal Fc receptor blocker, so it can lower harmful IgG antibodies. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 3 asset\u003c\/li\u003e\n\u003cli\u003e2025 sales: $0\u003c\/li\u003e\n\u003cli\u003eHigh unmet need markets\u003c\/li\u003e\n\u003cli\u003eNo commercial share yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat mix fits a classic Question Mark profile: high upside, no current revenue, and still dependent on trial readouts and launch timing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIcotrokinra: late-stage oral IL-23 program, zero 2025 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIcotrokinra is a late-stage oral IL-23 asset for psoriasis and other inflammatory disease markets that are large and still growing. As a precommercial program, its 2025 sales are zero and its BCG share is effectively 0.\u003c\/p\u003e\n\u003cp\u003eIn Johnson \u0026amp; Johnson's pipeline, that makes it a clear Question Mark: high market upside, no current revenue. If approval and uptake follow, it could move toward Star status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales: zero\u003c\/li\u003e\n\u003cli\u003eOral IL-23, late-stage\u003c\/li\u003e\n\u003cli\u003eHigh-growth inflammation market\u003c\/li\u003e\n\u003cli\u003ePotential future Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJ\u0026amp;J’s Oncology Question Marks: Small Today, Big Upside Tomorrow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s Question Marks are mostly oncology and pipeline assets with fast growth but low share. Carvykti led with 2024 sales of $963 million, while Tecvayli at about $0.5 billion and Talvey at $0.18 billion were still small. Nipocalimab and Icotrokinra had 2025 sales of $0 because they are still precommercial, so their upside depends on trial wins and launch scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Sales\u003c\/th\u003e\n\u003cth\u003eBCG View\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti\u003c\/td\u003e\n\u003ctd\u003e$963M\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTecvayli\u003c\/td\u003e\n\u003ctd\u003e~$0.5B\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalvey\u003c\/td\u003e\n\u003ctd\u003e~$0.18B\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNipocalimab\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIcotrokinra\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191851917577,"sku":"jnj-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/jnj-bcg-matrix.webp?v=1783678539","url":"https:\/\/dcfanalyst.com\/products\/jnj-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}